Puma Biotechnology Receives US FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire
Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® ( neratinib) | Business Wire
Neratinib Plus Capecitabine Approved for HER2-Positive Metastatic Breast Cancer
Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 | Business Wire
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Marketing Application for Early Stage Breast Cancer Therapy Neratinib Submitted to EMA by Puma Biotechnology - Breast Cancer News
Puma Biotech's Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer | Markets Insider
Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | FiercePharma
Puma's NERLYNX™ (Neratinib) An Extended Adjuvant Treatment For Breast Cancer: Approved by FDA - Scipreneur
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI | Business Wire
Puma Biotechnology sinks after Europe unlikely to OK breast cancer drug - Chemdiv
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | BioSpace
Puma Biotechnology SUMMIT Trial Update on Regulatory Strategy - ppt download
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology's Neratinib Set To Target Extended Adjuvant Opportunity (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib - Pharmaceutical Business review
Puma Biotechnology: Investors Didn't Like The EU/Africa Partnership Terms, But The Risk/Reward Is Attractive (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI | Business Wire
Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
